Description

AbbVie’s Skyrizi Surge: The Blockbuster Drug Defying Expectations & Dominating New Markets!

AbbVie recently reported its financial results for the second quarter of 2025, showcasing both achievements and challenges. AbbVie posted an adjusted earnings per share of $2.97, which surpassed their guidance midpoint by $0.11. Total net revenues came in at $15.4 billion, exceeding expectations by over $400 million. This revenue growth was driven by an impressive 22% sales increase from the ex-HUMIRA platform, especially through robust performances from Skyrizi and Rinvoq, with combined sales projected to surpass $25 billion this year. Based on these outcomes, AbbVie raised its full-year revenue guidance to $60.5 billion and adjusted EPS to between $11.88 and $12.08.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!